New progress of B7-H3 in glioma immunity

doi:10.3877/cma.j.issn.2095-9141.2019.01.012

Abstract

Abstract:

As a new member of B7-CD28 checkpoint pathway, B7-H3 plays an important role in tumor immunity. A large number of studies have shown that B7-H3 is highly expressed in most tumors and is associated with tumor immune escape. At the same time, it is also closely related to adhesion, invasion and metastasis of tumor. Athough B7-H3 related receptors have not been identified, the 8H9 antibodies against B7-H3 have been clinically successful. In this paper, the latest progress in the study of glioma immunity against B7-H3 is discussed.

Key words: B7-H3, Glioma, Immunotherapy

Jiayin Zhao, Yimin Fan. New progress of B7-H3 in glioma immunity[J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2019, 05(01): 56-59.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsjcswkdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9141.2019.01.012

https://zhsjcswkdzzz.cma-cmc.com.cn/EN/Y2019/V05/I01/56

References 37

[20]	Lee Y, Martinorozco N, Zheng P, et al. Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function[J]. Cell Res, 2017, 27(8):1034-1045.
[21]	Ling V, Wu PW, Spaulding V, et al. Duplication of primate and rodent B7-H3 immunoglobulin V- and C-like domains: divergent history of functional redundancy and exon loss[J]. Genomics, 2003, 82(3):365-377.
[22]	Prasad DV, Nguyen T, Li Z, et al. Murine B7-H3 is a negative regulator of T cells[J]. J Immunol, 2004, 173(4):2500-2506.
[23]	Ma J, Ma P, Zhao C, et al. B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy[J]. Oncotarget, 2016, 7(20):29480-29491.
[24]	Chen YW, Tekle C, Fodstad O. The immunoregulatory protein human B7H3 is a tumor-associated antigen that regulates tumor cell migration and invasion[J]. Curr Cancer Drug Targets, 2008, 8(5):404-413.
[25]	Tekle C, Nygren MK, Chen YW, et al. B7-H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes[J]. Int J Cancer, 2012, 130(10):2282-2290.
[26]	Kang FB, Wang L, Jia HC, et al. B7-H3 promotes aggression and invasion of hepatocellular carcinoma by targeting epithelial-to-mesenchymal transition via JAK2/STAT3/Slug signaling pathway[J]. Cancer Cell Int, 2015, 15:45.
[27]	Marimpietri D, Petretto A, Raffaghello L, et al. Proteome profiling of neuroblastoma-derived exosomes reveal the expression of proteins potentially involved in tumor progression[J]. PLoS One, 2013, 8(9):e75054.
[28]	Ricci-Vitiani L, Biffoni M, Todaro M, et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells[J]. Nature, 2010, 468(7325):824-828.
[29]	Gregorio A, Corrias MV, Castriconi R, et al. Small round blue cell tumours: diagnostic and prognostic usefulness of the expression of B7-H3 surface molecule[J]. Histopathology, 2008, 53(1):73-80.
[30]	Castriconi R, Dondero A, Negri F, et al. Both CD133+ and CD133-medulloblastoma cell lines express ligands for triggering NK receptors and are susceptible to NK-mediated cytotoxicity[J]. Eur J Immunol, 2007, 37(11):3190-3196.
[31]	Baral A, Ye HX, Jiang PC, et al. B7-H3 and B7-H1 expression in cerebral spinal fluid and tumor tissue correlates with the malignancy grade of glioma patients[J]. Oncol Lett, 2014, 8(3):1195-1201.
[32]	Zhou Z, Luther N, Ibrahim GM, et al. B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma[J]. J Neurooncol, 2013, 111(3):257-264.
[33]	Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy[J]. Nat Immunol, 2002, 3(7):611-618.
[34]	Loo D, Alderson RF, Chen FZ, et al. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity[J]. Clin Cancer Res, 2012, 18(14):3834-3845.
[35]	Ahmed M, Cheng M, Zhao Q, et al. Humanized affinity-matured monoclonal antibody 8H9 has potent antitumor activity and binds to FG loop of tumor antigen B7-H3[J]. J Biol Chem, 2015, 290(50):30018-30029.
[36]	Picarda E, Ohaegbulam KC, Zang X. Molecular pathways: targeting B7-H3 (CD276) for human cancer immunotherapy[J]. Clin Cancer Res, 2016, 22(14):3425-3431.
[37]	Yuan H, Wei X, Zhang G, et al. B7-H3 over expression in prostate cancer promotes tumor cell progression[J]. J Urol, 2011, 186(3):1093-1099.
[1]	Hakomori S. Tumor-associated carbohydrate antigens[J]. Annu Rev Immunol, 1984, 2:103-126.
[2]	Ladisch S, Wu ZL, Feig S, et al. Shedding of GD2 ganglioside by human neuroblastoma[J]. Int J Cancer, 1987, 39(1):73-76.
[3]	Valentino L, Moss T, Olson E, et al. Shed tumor gangliosides and progression of human neuroblastoma[J]. Blood, 1990, 75(7):1564-1567.
[4]	Sivori S, Parolini S, Marcenaro E. Involvement of natural cytotoxicity receptors in human natural killer cell-mediated lysis of neuroblastoma and glioblastoma cell lines[J]. J Neuroimmunol, 2000, 107(2):220-225.
[5]	Ruggeri L, Capanni M, Urbani E. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants[J]. Science, 2002, 295(5562):2097-1200.
[6]	Velardi A, Ruggeri L, Alessandro. NK cells: a lesson from mismatched hematopoietic transplantation[J]. Trends Immunol, 2002, 23(9):438-444.
[7]	Baral A, Ye HX, Jiang PC, et al. B7-H3 and B7-H1 expression in cerebral spinal fluid and tumor tissue correlates with the malignancy grade of glioma patients[J]. Oncol Lett, 2014, 8(3):1195-1201.
[8]	Zhou Z, Luther N, Ibrahim GM. B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma[J]. J Neurooncol, 2013, 111(3):257-264.
[9]	Hashiguchi M, Kobori H, Ritprajak P. Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses[J]. Proc Natl Acad Sci USA, 2008, 105(30):10495-10500.
[10]	Steinberger P, Majdic O, Derdak SV, et al. Molecular characterization of human 4Ig-B7-H3, a memberof the B7 family with four Ig-like domains[J]. J Immunol, 2004, 172:2352-2359.
[11]	Sun M, Richards S, Prasad DV, et al. Characterization of mouse and human B7-H3 genes[J]. J Immunol, 2002, 168(12):6294-6297.
[12]	Zhang G, Dong Q, Xu Y, et al. B7-H3: another molecule marker for Mo-DCs?[J]. Cell Mol Immunol, 2005, 2(4):307-311.
[13]	Chapoval AI, Ni J, Lau JS, et al. B7-H3: acostimulatory molecule for T cell activation and IFN-g production[J]. Nat Immunol, 2001, 2(3):269-274.
[14]	Sun J, Fu F, Gu W, et al. Origination of newimmunological functions in the costimulatory molecule B7-H3: the role of exon duplication in evolution of the immune system[J]. PLoS One, 2011, 6(9):e24751.
[15]	Zhang G, Hou J, Shi J, et al. Soluble CD276 (B7-H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum[J]. Immunology, 2008, 123(4):538-546.
[16]	Mahnke K, Ring S, Johnson TS, et al. Induction of immunosuppressive functions of dendritic cells in vivo by CD4+CD25+ regulatory T cells: role of B7-H3 expression and antigen presentation[J]. Eur J Immunol 2007, 37(8):2117-2608.
[17]	Suh WK, Gajewska BU, Okada H, et al. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses[J]. Nat Immunol, 2003, 4(9):899-906.
[18]	Wang Z, Yang J, Zhu Y, et al. Differential expression of 2IgB7-H3 and 4IgB7-H3 in cancer cell lines and glioma tissues[J]. Oncol Lett, 2015, 10(4):2204-2208.
[19]	Wang Z, Wang Z, Zhang C, et al. Genetic and clinical characterization of B7-H3(CD276) expression and epigenetic regulation in diffuse brain glioma[J]. Cancer Sci, 2018, 109(9):2697-2705.

Please choose a citation manager

Content to export